← Back to Search

Checkpoint Inhibitor

Treatment for Prostate Cancer

Phase 1
Waitlist Available
Led By Mark Scholz, MD
Research Sponsored by Prostate Oncology Specialists, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of the study, an expected average of 18 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of the study, an expected average of 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of the study, an expected average of 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Antibody responses against PA2024 and PAP
Antigen-specific T cell proliferation to PA2024, PAP and PHA
Antigen-specific memory T cell response
Secondary study objectives
Percentage PSA decline
Prostate-Specific Antigen (PSA) doubling time
Time to PSA progression
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment2 Interventions
Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sipuleucel-T
FDA approved
Ipilimumab
FDA approved

Find a Location

Who is running the clinical trial?

Prostate Oncology Specialists, Inc.Lead Sponsor
Mark Scholz, MDPrincipal InvestigatorProstate Oncology Specialists, Inc.
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top